Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose range finding study of MK-0893 in type 2 diabetes mellitus
2007-001691-36Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of MK-0893 in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Merck & Co. Primary endpoints: Fasting plasma glucose change at 12 weeks, HbA1c change at 12 weeks and 1 more. Started Jun 2007; status: completed.
02
Drugs
MK-0893
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2007-001691-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001691-36.